Summary of a meta analysis of over 1,000 cases of<unk>  and high-grade pediatric<unk> s, highlighting the mutations involved as well as generic outcome information.<unk>  has a 5-year survival rate of <1%. The median overall survival of children diagnosed with<unk>  is approximately 9 months. The 1- and 2-year survival rates are approximately 30% and less than 10%, respectively. These statistics make<unk>  one of the most devastating pediatric cancers. Although 75–85% of patients show some improvement in their symptoms after radiation therapy,<unk> s almost always begin to grow again (called recurrence, relapse, or progression). Clinical trials have reported that the median time between radiation therapy and progression is 5–8.8 months. Patients whose tumors begin to grow again may be eligible for experimental treatment through clinical trials to try to slow or stop the growth of the tumor. However, clinical trials have not shown any significant benefit from experimental<unk>  therapies so far.<unk> s that progress usually grow quickly and affect important parts of the brain. The median time from tumor progression to death is usually very short, between 1 and 4.5 months. During this time, doctors focus on palliative care: controlling symptoms and making the patient as comfortable as possible.
Diffuse intrinsic pontine glioma
Giant-cell glioblastoma
Fibrillary astrocytoma
Subependymal giant cell astrocytoma
Brainstem glioma
Intraneural perineurioma
Pilocytic astrocytoma
Anaplastic astrocytoma